MENU
APR 14, 2021 7:30 AM PDT

Keynote Presentation: The impact of the New COVID-19 Variants and Vaccine Rollout on the pandemic

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Chief Strategy Officer, Population Health, University of Washington
    Biography

      Ali H. Mokdad, PhD, is Professor of Health Metrics Sciences at the Institute for Health Metrics and Evaluation (IHME) and Chief Strategy Officer for Population Health at the University of Washington. Prior to IHME, Dr. Mokdad worked at the US Centers for Disease Control and Prevention. He has published groundbreaking research on local-level disease trends and leading risk factors for poor health. His work on obesity is among the most highly cited in the field.


    Abstract

    The Institute for Health Metrics and Evaluation (IHME) uses a hybrid modeling approach to generate Covid19 forecasts. The model incorporates elements of statistical and disease transmission models and is grounded primarily in real-time data instead of assumptions about how the disease will spread. The model accounts for several variables including mobility, mask wearing, testing, and the spread of the new variants. New variants have the potential to increase transmission, escape immunity from previous infections, and reduce the effectiveness of the vaccines. Our long-term projections show that there is a potential of a rise in cases and deaths due to the new variants. The future of the pandemic depends on the behavioral response in terms of vaccine confidence, mask wearing, and avoidance of situations that pose a high-risk for transmission.
     
    Learning Objectives:

    1. The seminar will help understand the future scenarios for the spread of the virus

    2. The seminar will allow attendees to understand how IHME models covid19

    3. The seminar will explain the impact of the new variants on the pandemic and how we can best respond to their challenge


    Show Resources
    You May Also Like
    DEC 03, 2020 4:30 PM PST
    C.E. CREDITS
    DEC 03, 2020 4:30 PM PST
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    FEB 24, 2021 10:00 AM PST
    C.E. CREDITS
    FEB 24, 2021 10:00 AM PST
    DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
    C.E. CREDITS
    Antibody tests are important tools to assess the efficacy of vaccine candidates and to derive suitable vaccination modalities. High specificity and sensitivity are of great importance for th...
    JAN 21, 2021 8:00 AM PST
    JAN 21, 2021 8:00 AM PST
    Date: January 21, 2021 Time: 8:00am (PST), 11:00am (EST) Today, critical reagent characterization is a key component in the overall workflow to establish robust ligand binding assays (e.g.,...
    DEC 03, 2020 10:30 AM PST
    C.E. CREDITS
    DEC 03, 2020 10:30 AM PST
    The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019 and has spread globally, causing a pandemic of respiratory illness designated coronavirus disease 20...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    Loading Comments...
    Show Resources
    Attendees
    • See more